Skip to main content
Top
Published in: BMC Clinical Pharmacology 1/2012

Open Access 01-12-2012 | Research article

Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement

Authors: Tobias Dreischulte, Aileen M Grant, Colin McCowan, John J McAnaw, Bruce Guthrie

Published in: BMC Clinical Pharmacology | Issue 1/2012

Login to get access

Abstract

Background

Addressing the problem of preventable drug related morbidity (PDRM) in primary care is a challenge for health care systems internationally. The increasing implementation of clinical information systems in the UK and internationally provide new opportunities to systematically identify patients at risk of PDRM for targeted medication review. The objectives of this study were (1) to develop a set of explicit medication assessment criteria to identify patients with sub-optimally effective or high-risk medication use from electronic medical records and (2) to identify medication use topics that are perceived by UK primary care clinicians to be priorities for quality and safety improvement initiatives.

Methods

For objective (1), a 2-round consensus process based on the RAND/UCLA Appropriateness Method (RAM) was conducted, in which candidate criteria were identified from the literature and scored by a panel of 10 experts for 'appropriateness' and 'necessity'. A set of final criteria was generated from candidates accepted at each level. For objective (2), thematically related final criteria were clustered into 'topics', from which a panel of 26 UK primary care clinicians identified priorities for quality improvement in a 2-round Delphi exercise.

Results

(1) The RAM process yielded a final set of 176 medication assessment criteria organised under the domains 'quality' and 'safety', each classified as targeting 'appropriate/necessary to do' (quality) or 'inappropriate/necessary to avoid' (safety) medication use. Fifty-two final 'quality' assessment criteria target patients with unmet indications, sub-optimal selection or intensity of beneficial drug treatments. A total of 124 'safety' assessment criteria target patients with unmet needs for risk-mitigating agents, high-risk drug selection, excessive dose or duration, inconsistent monitoring or dosing instructions. (2) The UK Delphi panel identified 11 (23%) of 47 scored topics as 'high priority' for quality improvement initiatives in primary care.

Conclusions

The developed criteria set complements existing medication assessment instruments in that it is not limited to the elderly, can be implemented in electronic data sets and focuses on drug groups and conditions implicated in common and/or severe PDRM in primary care. Identified priorities for quality and safety improvement can guide the selection of targets for initiatives to address the PDRM problem in primary care.
Literature
1.
go back to reference Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M: Which drugs cause preventable admissions to hospital? A systematic review. British Journal of Clinical Pharmacology. 2006, 63 (2): 136-147.CrossRefPubMedPubMedCentral Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M: Which drugs cause preventable admissions to hospital? A systematic review. British Journal of Clinical Pharmacology. 2006, 63 (2): 136-147.CrossRefPubMedPubMedCentral
2.
go back to reference Pirmohamed MJ, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM: Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004, 329: 15-19. 10.1136/bmj.329.7456.15.CrossRefPubMedPubMedCentral Pirmohamed MJ, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM: Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004, 329: 15-19. 10.1136/bmj.329.7456.15.CrossRefPubMedPubMedCentral
3.
go back to reference Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A: Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care. The Annals of Pharmacotherapy. 2007, 41: 1411-1426. 10.1345/aph.1H658.CrossRefPubMed Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A: Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care. The Annals of Pharmacotherapy. 2007, 41: 1411-1426. 10.1345/aph.1H658.CrossRefPubMed
4.
go back to reference Winterstein AG SB, Hepler CD, Poole C: Preventable drug related hospital admissions. Ann Pharmacother. 2002, 36: 1238-1248.CrossRefPubMed Winterstein AG SB, Hepler CD, Poole C: Preventable drug related hospital admissions. Ann Pharmacother. 2002, 36: 1238-1248.CrossRefPubMed
6.
go back to reference Medicines and Healthcare Products Regulatory Agency CoHM: Antipsychotics: use in elderly people with dementia. Drug Saf Update. 2009, 2 (8): Medicines and Healthcare Products Regulatory Agency CoHM: Antipsychotics: use in elderly people with dementia. Drug Saf Update. 2009, 2 (8):
7.
go back to reference Howard R, Avery A, Bissell P: Causes of preventable drug-related hospital admissions: a qualitative study. Qual Saf Health Care. 2007, 17: 109-116.CrossRef Howard R, Avery A, Bissell P: Causes of preventable drug-related hospital admissions: a qualitative study. Qual Saf Health Care. 2007, 17: 109-116.CrossRef
8.
go back to reference Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH: Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: Results of a US Consensus Panel of Experts. Arch Intern Med. 2003, 163 (22): 2716-2724. 10.1001/archinte.163.22.2716.CrossRefPubMed Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH: Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: Results of a US Consensus Panel of Experts. Arch Intern Med. 2003, 163 (22): 2716-2724. 10.1001/archinte.163.22.2716.CrossRefPubMed
9.
go back to reference Shekelle PG, MacLean CH, Morton SC, Wenger NS: Acove quality indicators. Annals of Internal Medicine. 2001, 135 (8 Pt 2): 653-667.PubMed Shekelle PG, MacLean CH, Morton SC, Wenger NS: Acove quality indicators. Annals of Internal Medicine. 2001, 135 (8 Pt 2): 653-667.PubMed
10.
go back to reference Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D: STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. International Journal of Clinical Pharmacology & Therapeutics. 2008, 46 (2): 72-83.CrossRef Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D: STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. International Journal of Clinical Pharmacology & Therapeutics. 2008, 46 (2): 72-83.CrossRef
13.
go back to reference Wessell AM, Litvin C, Jenkins RG, Nietert PJ, Nemeth LS, Ornstein SM: Medication prescribing and monitoring errors in primary care: a report from the Practice Partner Research Network. Quality & Safety in Health Care. 2010, 19 (5): e21- Wessell AM, Litvin C, Jenkins RG, Nietert PJ, Nemeth LS, Ornstein SM: Medication prescribing and monitoring errors in primary care: a report from the Practice Partner Research Network. Quality & Safety in Health Care. 2010, 19 (5): e21-
14.
go back to reference Strand LM, Cipolle RJ, Morley PC, Frakes MJ: The impact of Pharmaceutical care Practice on the practitioner and the patient in the ambulatory care setting: 25 years of experience. Current Pharmaceutical Design. 2004, 3987-4001. Strand LM, Cipolle RJ, Morley PC, Frakes MJ: The impact of Pharmaceutical care Practice on the practitioner and the patient in the ambulatory care setting: 25 years of experience. Current Pharmaceutical Design. 2004, 3987-4001.
15.
go back to reference Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BH: A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf. 2010, 19 (4): 319-334.PubMed Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BH: A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf. 2010, 19 (4): 319-334.PubMed
16.
go back to reference The American College of Cardiology and American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation): ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006, 8 (9): 651-745.CrossRef The American College of Cardiology and American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation): ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006, 8 (9): 651-745.CrossRef
19.
go back to reference National Institute for Health and Clinical Excellence: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE Technology appraisal guidance number 161. National Institute for Health and Clinical Excellence, London. 2008, Available at http://www.nice.org.uk/nicemedia/pdf/TA160guidance.pdf National Institute for Health and Clinical Excellence: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE Technology appraisal guidance number 161. National Institute for Health and Clinical Excellence, London. 2008, Available at http://​www.​nice.​org.​uk/​nicemedia/​pdf/​TA160guidance.​pdf
25.
go back to reference The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure. 2008, 10 (10): 933-989. 10.1016/j.ejheart.2008.08.005.CrossRef The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure. 2008, 10 (10): 933-989. 10.1016/j.ejheart.2008.08.005.CrossRef
26.
go back to reference Komajda M, Drexler H: Lessons from the European heart survey. Circulation. 2006, 113 (7): f25-26.PubMed Komajda M, Drexler H: Lessons from the European heart survey. Circulation. 2006, 113 (7): f25-26.PubMed
27.
go back to reference Anselmino M, Bartnik M, Malmberg K, Ryden L: Euro Heart Survey I: Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. European Journal of Cardiovascular Prevention & Rehabilitation. 2007, 14 (1): 28-36. 10.1097/01.hjr.0000199496.23838.83.CrossRef Anselmino M, Bartnik M, Malmberg K, Ryden L: Euro Heart Survey I: Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. European Journal of Cardiovascular Prevention & Rehabilitation. 2007, 14 (1): 28-36. 10.1097/01.hjr.0000199496.23838.83.CrossRef
28.
go back to reference Leiter LA, Betteridge DJ, Chacra AR, Chait A, Ferrannini E, Haffner SM, Kadowaki T, Tuomilehto J, Zimmet P, Newman CB, Hey-Hadavi J, Walkinshaw C: AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. The British Journal of Diabetes & Vascular Disease. 2006, 6 (1): 31-40. 10.1177/14746514060060010401.CrossRef Leiter LA, Betteridge DJ, Chacra AR, Chait A, Ferrannini E, Haffner SM, Kadowaki T, Tuomilehto J, Zimmet P, Newman CB, Hey-Hadavi J, Walkinshaw C: AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. The British Journal of Diabetes & Vascular Disease. 2006, 6 (1): 31-40. 10.1177/14746514060060010401.CrossRef
29.
go back to reference Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J: The EuroHeart Failure survey programme--a survey on the quality of care among patients with heart failure in Europe. European Heart Journal. 2003, 24 (5): 442-463.CrossRefPubMed Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J: The EuroHeart Failure survey programme--a survey on the quality of care among patients with heart failure in Europe. European Heart Journal. 2003, 24 (5): 442-463.CrossRefPubMed
30.
go back to reference Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey J-Y, Prins MH, Levy S, Crijns H: Atrial fibrillation management: a prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. European Heart Journal. 2005, 26 (22): 2422-2434. 10.1093/eurheartj/ehi505.CrossRefPubMed Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey J-Y, Prins MH, Levy S, Crijns H: Atrial fibrillation management: a prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. European Heart Journal. 2005, 26 (22): 2422-2434. 10.1093/eurheartj/ehi505.CrossRefPubMed
31.
go back to reference Turner S, Thomas M, von Ziegenweidt J, Price D: Prescribing trends in asthma: a longitudinal observational study. Archives of Disease in Childhood. 2009, 94 (1): 16-22. 10.1136/adc.2008.140681.CrossRefPubMed Turner S, Thomas M, von Ziegenweidt J, Price D: Prescribing trends in asthma: a longitudinal observational study. Archives of Disease in Childhood. 2009, 94 (1): 16-22. 10.1136/adc.2008.140681.CrossRefPubMed
32.
go back to reference Feldstein AC, Elmer PJ, Nichols GA, Herson M: Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis International. 2005, 16 (12): 2168-2174. 10.1007/s00198-005-2016-z.CrossRefPubMed Feldstein AC, Elmer PJ, Nichols GA, Herson M: Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis International. 2005, 16 (12): 2168-2174. 10.1007/s00198-005-2016-z.CrossRefPubMed
33.
go back to reference Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE: Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporosis International. 2004, 15 (10): 767-778.CrossRefPubMed Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE: Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporosis International. 2004, 15 (10): 767-778.CrossRefPubMed
34.
go back to reference Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW, Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003, 289 (9): 1107-1116. 10.1001/jama.289.9.1107.CrossRefPubMed Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW, Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003, 289 (9): 1107-1116. 10.1001/jama.289.9.1107.CrossRefPubMed
35.
go back to reference Stockley's drug interactions. [online]. Edited by: Baxter K. 2009, Pharmaceutical Press, London Stockley's drug interactions. [online]. Edited by: Baxter K. 2009, Pharmaceutical Press, London
36.
go back to reference Joint Formulary Committee (British Medical Association and The Royal Pharmaceutical Society of Great Britain): British National Formulary. 2009, London, 57: Joint Formulary Committee (British Medical Association and The Royal Pharmaceutical Society of Great Britain): British National Formulary. 2009, London, 57:
40.
go back to reference Morris CJ, Cantrill JA: Preventing drug-related morbidity-the development of quality indicators. Journal of Clinical Pharmacy & Therapeutics. 2003, 28 (4): 295-305. 10.1046/j.1365-2710.2003.00496.x.CrossRef Morris CJ, Cantrill JA: Preventing drug-related morbidity-the development of quality indicators. Journal of Clinical Pharmacy & Therapeutics. 2003, 28 (4): 295-305. 10.1046/j.1365-2710.2003.00496.x.CrossRef
41.
go back to reference Campbell SM, Braspenning J, Hutchinson A, Marshall MN: Research methods used in developing and applying quality indicators in primary care. BMJ. 2003, 326 (7393): 816-819. 10.1136/bmj.326.7393.816.CrossRefPubMedPubMedCentral Campbell SM, Braspenning J, Hutchinson A, Marshall MN: Research methods used in developing and applying quality indicators in primary care. BMJ. 2003, 326 (7393): 816-819. 10.1136/bmj.326.7393.816.CrossRefPubMedPubMedCentral
42.
go back to reference Shekelle PG, MacLean CH, Morton SC, Wenger NS: Assessing Care of Vulnerable Elders: Methods for Developing Quality Indicators. Annals of Internal Medicine. 2001, 135 (8 Part 2): 647-652.CrossRefPubMed Shekelle PG, MacLean CH, Morton SC, Wenger NS: Assessing Care of Vulnerable Elders: Methods for Developing Quality Indicators. Annals of Internal Medicine. 2001, 135 (8 Part 2): 647-652.CrossRefPubMed
43.
go back to reference Kahan JP BS, Leape LL: Measuring the necessity of medical procedures. Med Care. 1994, 32 (357): 365. Kahan JP BS, Leape LL: Measuring the necessity of medical procedures. Med Care. 1994, 32 (357): 365.
44.
go back to reference Naylor CD: What is appropriate care?. N Engl J Med. 1998, 338: 1918-1920. 10.1056/NEJM199806253382612.CrossRefPubMed Naylor CD: What is appropriate care?. N Engl J Med. 1998, 338: 1918-1920. 10.1056/NEJM199806253382612.CrossRefPubMed
45.
go back to reference Shekelle PG: Are appropriateness criteria ready for use in clinical practice?. NEngl JMed. 2001, 344 (9): 677-678. 10.1056/NEJM200103013440912.CrossRef Shekelle PG: Are appropriateness criteria ready for use in clinical practice?. NEngl JMed. 2001, 344 (9): 677-678. 10.1056/NEJM200103013440912.CrossRef
46.
go back to reference Brook RH CM, Fink A: A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986, 2: 53-63. 10.1017/S0266462300002774.CrossRefPubMed Brook RH CM, Fink A: A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986, 2: 53-63. 10.1017/S0266462300002774.CrossRefPubMed
47.
go back to reference Leape LL, Park RE, Kahan JP, Brook RH: Group judgements of appropriateness: the effect of panel composition. Quality Assurance Health Care. 1992, 4: 151-159. Leape LL, Park RE, Kahan JP, Brook RH: Group judgements of appropriateness: the effect of panel composition. Quality Assurance Health Care. 1992, 4: 151-159.
48.
go back to reference Campbell SM, Cantrill JA: Consensus methods in prescribing research. Journal of Clinical Pharmacy & Therapeutics. 2001, 26 (1): 5-14. 10.1046/j.1365-2710.2001.00331.x.CrossRef Campbell SM, Cantrill JA: Consensus methods in prescribing research. Journal of Clinical Pharmacy & Therapeutics. 2001, 26 (1): 5-14. 10.1046/j.1365-2710.2001.00331.x.CrossRef
49.
go back to reference Morris CJ, Cantrill JA, Hepler CD, Noyce PR: Preventing drug-related morbidity-determining valid indicators. International Journal for Quality in Health Care. 2002, 14 (3): 183-198.CrossRefPubMed Morris CJ, Cantrill JA, Hepler CD, Noyce PR: Preventing drug-related morbidity-determining valid indicators. International Journal for Quality in Health Care. 2002, 14 (3): 183-198.CrossRefPubMed
50.
go back to reference Bigby J, Dunn J, Goldman L, Adams JB, Jen P LC, Komaroff AL: Assessing the preventability of emergency hospital admissions. A method for evaluating the quality of medical care in a primary care facility. Am J Med. 1987, 83: 1031-1036. 10.1016/0002-9343(87)90938-7.CrossRefPubMed Bigby J, Dunn J, Goldman L, Adams JB, Jen P LC, Komaroff AL: Assessing the preventability of emergency hospital admissions. A method for evaluating the quality of medical care in a primary care facility. Am J Med. 1987, 83: 1031-1036. 10.1016/0002-9343(87)90938-7.CrossRefPubMed
51.
go back to reference Chan M, Nicklason F, Vial JH: Adverse drug events as a cause of hospital admission in the elderly. Intern Med. 2001, 31: 199-205. 10.1046/j.1445-5994.2001.00044.x.CrossRef Chan M, Nicklason F, Vial JH: Adverse drug events as a cause of hospital admission in the elderly. Intern Med. 2001, 31: 199-205. 10.1046/j.1445-5994.2001.00044.x.CrossRef
52.
go back to reference Courtman BJ, Stallings SB: Characterisation of drug-related problems in elderly patients on admissions to a medical ward. Can J Hosp Pharm. 1995, 48: 161-166.PubMed Courtman BJ, Stallings SB: Characterisation of drug-related problems in elderly patients on admissions to a medical ward. Can J Hosp Pharm. 1995, 48: 161-166.PubMed
53.
go back to reference Ajzen I: The theory of planned behaviour. Organizational behaviour and human decision processes. 1991, 50: 170-211.CrossRef Ajzen I: The theory of planned behaviour. Organizational behaviour and human decision processes. 1991, 50: 170-211.CrossRef
54.
go back to reference Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K: High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011, 342: d3514-10.1136/bmj.d3514.CrossRefPubMed Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K: High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011, 342: d3514-10.1136/bmj.d3514.CrossRefPubMed
55.
go back to reference Fitch K, Bernstein S, Aguilar M, Burnand B, LaCalle J, Lazaro P: The RAND/UCLA appropriateness method user's manual. RAND Corporation. 2003 Fitch K, Bernstein S, Aguilar M, Burnand B, LaCalle J, Lazaro P: The RAND/UCLA appropriateness method user's manual. RAND Corporation. 2003
Metadata
Title
Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement
Authors
Tobias Dreischulte
Aileen M Grant
Colin McCowan
John J McAnaw
Bruce Guthrie
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Clinical Pharmacology / Issue 1/2012
Electronic ISSN: 1472-6904
DOI
https://doi.org/10.1186/1472-6904-12-5

Other articles of this Issue 1/2012

BMC Clinical Pharmacology 1/2012 Go to the issue